Cavion – $26 Million Series A Financing

Reston – January 19, 2017 – Cooley advised Cavion on its $26.1 million Series A financing round. Lilly Ventures and Novartis Venture Fund co-led the round, with additional participation from Enso Ventures and other existing investors.

According to Cavion, the funding will support the development of novel treatments for neurological diseases. Later this year, the company plans to conduct a robust proof-of-concept Phase 2 study of its Cav3 inhibitor CX-8998 for the treatment of essential tremor.

“Cavion’s compelling science and its Cav3 modulators offer a unique opportunity to develop effective therapies for patients with medical needs unmet in the neurological field,” said Dr. Sergei Petukhov, partner at Enso Ventures, in a press release issued by Cavion.

Cavion, based in Charlottesville, Virginia, is a privately held, clinical stage biotechnology company creating therapies for the treatment of neurological and oncologic diseases.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.